Microdose follicular phase gonadotropin-releasing hormone agonists (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization

Mark P. Leondires, Mariabelle Escalpes, James H. Segars, Richard T. Scott, Bradley T. Miller

Research output: Contribution to journalArticle

Abstract

Objective: To compare an ovarian stimulation protocol using microdose follicular phase GnRH agonist (GnRH-a) and oral contraceptive (OC) pills to a luteal phase GnRH-a protocol. Design: Retrospective analysis. Setting: University affiliated IVF program. Patient(s): One hundred seventy patients who underwent IVF and ET in 1996. Intervention(s): Patients were assigned to either a midluteal start of leuprolide acetate (LA) 1 mg/d, reduced to 0.5 mg/d after addition of gonadotropins (LUT), or OC pills until cycle day 0 followed by 20 μg of LA every 12 hours on cycle day 3 with addition of gonadotropins on cycle day 5 (MICRO). Main Outcome Measure(s): Number of FSH ampules, days of stimulation, peak E2, and number of oocytes retrieved. Result(s): There were no statistically significant differences in the main outcome measures between the two groups using an age-matched ANOVA. Clinical pregnancy rate per cycle start was not statistically different (LUT = 54%, and MICRO = 37%). The cancellation rate was significantly higher in the MICRO group (22.5% vs. 8.2%). Conclusion(s): Given the higher cancellation rate in the microdose group, a randomized clinical trial is required to determine the possible benefit of a lower dose of GnRH-a in patients with normal ovarian function.

Original languageEnglish (US)
Pages (from-to)1018-1023
Number of pages6
JournalFertility and sterility
Volume72
Issue number6
DOIs
StatePublished - Dec 1 1999
Externally publishedYes

Keywords

  • Cost efficiency
  • In vitro fertilization
  • Microdose GnRH-a

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Microdose follicular phase gonadotropin-releasing hormone agonists (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization'. Together they form a unique fingerprint.

  • Cite this